An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia

Leukemia Research

Volumn 34, Issue 2, 2010, Pages 196-202

  Fiedler, Walter ^a   Mesters, Rolf ^b   Heuser, Michael ^c   Ehninger, Gerhard ^d   Berdel, Wolfgang E ^b   Zirrgiebel, Ute ^e   Robertson, Jane D ^f   Puchalski, Tom A ^f   Collins, Barbara ^f   Jürgensmeier, Juliane M ^f   Serve, Hubert ^b,g  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e PROQINASE GMBH   (Germany)

^f ASTRAZENECA   (United Kingdom)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Acute myeloid leukemia; Angiogenesis; Cediranib; Vascular endothelial growth factor

Indexed keywords

CEDIRANIB; STEM CELL FACTOR; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANGIOGENESIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SIGNAL TRANSDUCTION; STEADY STATE; THYROTROPIN BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION;

AGED; AGED, 80 AND OVER; DIARRHEA; FATIGUE; FEMALE; HUMANS; HYPERTENSION; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PILOT PROJECTS; PROTO-ONCOGENE PROTEINS C-KIT; QUINAZOLINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 74849101514     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.07.020     Document Type: Article

References (31)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2004, National Cancer Institute. Bethesda; 2008. Available at: http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER website; 2007.
3. Stone R.M. Novel therapeutic agents in acute myeloid leukemia. Exp Hematol 35 (2007) 163-166
4. Dong X., Han Z.C., and Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol 62 (2007) 105-118
5. Aguayo A., Estey E., Kantarjian H., Mansouri T., Gidel C., Keating M., et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94 (1999) 3717-3721
6. Bieker R., Padro T., Kramer J., Steins M., Kessler T., Retzlaff S., et al. Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res 63 (2003) 7241-7246
7. Kuzu I., Beksac M., Arat M., Celebi H., Elhan A.H., and Erekul S. Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymphoma 45 (2004) 1185-1190
8. Padro T., Bieker R., Ruiz S., Steins M., Retzlaff S., Burger H., et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 16 (2002) 1302-1310
9. Fiedler W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M., et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89 (1997) 1870-1875
10. Dias S., Choy M., Alitalo K., and Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99 (2002) 2179-2184
11. Liersch R., Schliemann C., Bieker R., Hintelmann H., Buechner T., Berdel W.E., et al. Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia. Leuk Res 32 (2008) 954-961
12. Fiedler W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M., et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 11 (1997) 1234-1237
13. Kanakura Y., Ikeda H., Kitayama H., Sugahara H., and Furitsu T. Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells. Leuk Lymphoma 10 (1993) 35-41
14. Muroi K., Nakamura M., Amemiya Y., Suda T., and Miura Y. Expression of c-kit receptor (CD117) and CD34 in leukemic cells. Leuk Lymphoma 16 (1995) 297-305
15. Gari M., Goodeve A., Wilson G., Winship P., Langabeer S., Linch D., et al. c-Kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 105 (1999) 894-900
16. Longley B.J., Reguera M.J., and Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25 (2001) 571-576
17. Moreira A.L., Friedlander D.R., Shif B., Kaplan G., and Zagzag D. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol 43 (1999) 109-114
18. O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003) 3597-3605
19. Fiedler W., Serve H., Dohner H., Schwittay M., Ottmann O.G., O'Farrell A.M., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
20. Wedge S.R., Kendrew J., Hennequin L.F., Valentine P.J., Barry S.T., Brave S.R., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65 (2005) 4389-4400
21. Drevs J., Siegert P., Medinger M., Mross K., Strecker R., Zirrgiebel U., et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25 (2007) 3045-3054
22. Padro T., Ruiz S., Bieker R., Burger H., Steins M., Kienast J., et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95 (2000) 2637-2644
23. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21 (2003) 4642-4649
24. Langenberg M., van Herpen C.M., de Bono J.S., Unger C., Schellens J.H., Hoekman K., et al. Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: a randomized phase II study of cediranib. J Clin Oncol 26 15S (2008) abst 3555
25. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
26. Karakunnel J.J., Gulley J.L., Arlen P.M., Mulquin M., Wright J.J., Turkbey I.B., et al. Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC). J Clin Oncol 26 15S (2008) abst 5136
27. Loges S., Tinnefeld H., Metzner A., Jucker M., Butzal M., Bruweleit M., et al. Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416. Leuk Lymphoma 47 (2006) 2601-2609
28. O'Farrell A.M., Foran J.M., Fiedler W., Serve H., Paquette R.L., Cooper M.A., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9 (2003) 5465-5476
29. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
30. Matulonis U.A., Berlin S.T., Krasner C.N., Tyburski K., Lee J., Roche M., et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 26 15S (2008) abst 5501
31. van Herpen C., Drevs J., van Cruijsen H., Voest E.E., Punt C.J., Robertson J., et al. Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): combined results from two phase I studies. J Clin Oncol 25 18S (2007) abst 3560